Clinical trial
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not…
NCT00053222 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00053222 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine |
| Official title | A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 13 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Jan 28, 2003 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: